140 related articles for article (PubMed ID: 29995421)
1. Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
Orlova A; Bass TZ; Rinne SS; Leitao CD; Rosestedt M; Atterby C; Gudmundsdotter L; Frejd FY; Löfblom J; Tolmachev V; Ståhl S
Mol Pharm; 2018 Aug; 15(8):3394-3403. PubMed ID: 29995421
[TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.
Bass TZ; Rosestedt M; Mitran B; Frejd FY; Löfblom J; Tolmachev V; Ståhl S; Orlova A
Sci Rep; 2017 Feb; 7():43118. PubMed ID: 28230065
[TBL] [Abstract][Full Text] [Related]
3. Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.
Altai M; Leitao CD; Rinne SS; Vorobyeva A; Atterby C; Ståhl S; Tolmachev V; Löfblom J; Orlova A
Cells; 2018 Oct; 7(10):. PubMed ID: 30314301
[TBL] [Abstract][Full Text] [Related]
4. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model.
Leitao CD; Rinne SS; Altai M; Vorontsova O; Dunås F; Jonasson P; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32545760
[TBL] [Abstract][Full Text] [Related]
6. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
Curley MD; Sabnis GJ; Wille L; Adiwijaya BS; Garcia G; Moyo V; Kazi AA; Brodie A; MacBeath G
Mol Cancer Ther; 2015 Nov; 14(11):2642-52. PubMed ID: 26310543
[TBL] [Abstract][Full Text] [Related]
7. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
Kawakami H; Okamoto I; Yonesaka K; Okamoto K; Shibata K; Shinkai Y; Sakamoto H; Kitano M; Tamura T; Nishio K; Nakagawa K
Oncotarget; 2014 Dec; 5(23):11847-56. PubMed ID: 25474137
[TBL] [Abstract][Full Text] [Related]
8. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915
[TBL] [Abstract][Full Text] [Related]
9. HER3-Targeted Affibodies with Optimized Formats Reduce Ovarian Cancer Progression in a Mouse Xenograft Model.
Schardt JS; Noonan-Shueh M; Oubaid JM; Pottash AE; Williams SC; Hussain A; Lapidus RG; Lipkowitz S; Jay SM
AAPS J; 2019 Apr; 21(3):48. PubMed ID: 30949858
[TBL] [Abstract][Full Text] [Related]
10. HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy.
Kawakami H; Yonesaka K
Recent Pat Anticancer Drug Discov; 2016; 11(3):267-74. PubMed ID: 27086600
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.
Andersson KG; Rosestedt M; Varasteh Z; Malm M; Sandström M; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Oncol Rep; 2015 Aug; 34(2):1042-8. PubMed ID: 26059265
[TBL] [Abstract][Full Text] [Related]
12. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
13. HER3 PET Imaging:
Rinne SS; Leitao CD; Abouzayed A; Vorobyeva A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638277
[TBL] [Abstract][Full Text] [Related]
14. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
15. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Le Clorennec C; Bazin H; Dubreuil O; Larbouret C; Ogier C; Lazrek Y; Garambois V; Poul MA; Mondon P; Barret JM; Mathis G; Prost JF; Pèlegrin A; Chardès T
Mol Cancer Ther; 2017 Jul; 16(7):1312-1323. PubMed ID: 28507002
[TBL] [Abstract][Full Text] [Related]
16. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
17. HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
[TBL] [Abstract][Full Text] [Related]
18. Cellular effects of HER3-specific affibody molecules.
Göstring L; Malm M; Höidén-Guthenberg I; Frejd FY; Ståhl S; Löfblom J; Gedda L
PLoS One; 2012; 7(6):e40023. PubMed ID: 22768204
[TBL] [Abstract][Full Text] [Related]
19. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
20. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
Malm M; Bass T; Gudmundsdotter L; Lord M; Frejd FY; Ståhl S; Löfblom J
Biotechnol J; 2014 Sep; 9(9):1215-22. PubMed ID: 24678002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
